Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation will highlight findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics, underscoring the importance of tissue-level drug distribution in determining toxicity profiles.
The research supports the development of improved drug delivery strategies, including intravenous and nanoparticle-based formulations. This approach could lead to more precise targeting of therapeutic agents while minimizing adverse effects on healthy tissues. The full press release detailing this announcement is available at https://ibn.fm/kZzE3.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. The company's work represents a significant advancement in how pharmaceutical compounds are delivered within the body, potentially revolutionizing treatment approaches for various conditions.
Oncotelic, the parent company, is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. The company has rare pediatric designation for Diffuse Intrinsic Pontine Glioma through OT-101 via its 45% joint venture GMP Bio, as well as designations for melanoma and Acute Myeloid Leukemia through other compounds.
The presentation at SOT 2026 represents an important milestone in understanding how drugs like everolimus behave at the tissue level rather than just in plasma. This distinction is crucial because traditional pharmacokinetic measurements in blood plasma may not accurately reflect how drugs distribute to and affect specific organs and tissues. By focusing on tissue concentration–driven effects, researchers can better predict and manage potential toxicities associated with drug treatments.
For investors and stakeholders following Oncotelic's progress, the latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. The presentation at this major scientific conference positions Sapu Nano's research within the broader context of toxicology and drug development, potentially influencing how future therapies are designed and evaluated for safety.
The implications of this research extend beyond oncology applications, as improved understanding of tissue-level drug distribution could inform development across multiple therapeutic areas. By moving beyond traditional plasma pharmacokinetics, researchers may identify more accurate predictors of drug efficacy and safety, ultimately leading to better patient outcomes and more targeted therapeutic interventions.
